Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure.
Summary
Cardiomyocyte IRF3 is phosphorylated and activated in ischemic cardiomyopathy, repressing Ppargc1α and disrupting mitochondrial energetics, metabolic flux, and redox state, which worsens cardiac function. Restoring Ppargc1α in cardiomyocytes rescues function, positioning IRF3–PGC-1α as a central inflammatory–metabolic axis in heart failure.
Key Findings
- IRF3 phosphorylation (Ser396/Ser398) is elevated in human and mouse ischemic cardiomyopathy myocardium.
- Cardiomyocyte-specific IRF3 activation represses Ppargc1α, impairing OXPHOS, altering PPP/TCA flux, and disrupting NAD metabolism with excessive type I IFN activation.
- Genetic restoration of Ppargc1α in cardiomyocytes rescues contractile dysfunction by shifting substrate use toward fatty acid oxidation and dampening inflammatory-fibrotic responses.
Clinical Implications
Pharmacologic modulation of IRF3 signaling or boosting PGC-1α activity could restore myocardial energetics and blunt inflammatory remodeling in ischemic cardiomyopathy, informing drug discovery and precision therapeutics.
Why It Matters
The study reveals a direct transcriptional link between type I IFN signaling and mitochondrial energetics in cardiomyocytes, offering a tractable axis (IRF3–PGC‑1α) for therapeutic targeting in ischemic cardiomyopathy.
Limitations
- Predominant use of male mice may limit generalizability across sexes
- Preclinical nature without pharmacologic IRF3 inhibition tested in vivo
Future Directions
Develop selective IRF3 modulators and PGC-1α enhancers; assess sex-specific effects; validate biomarkers of IRF3–PGC‑1α activity in patients to enable targeted trials.
Study Information
- Study Type
- Basic/Mechanistic study
- Research Domain
- Pathophysiology
- Evidence Level
- V - Mechanistic preclinical study in human tissue samples and mouse models with genetic manipulation
- Study Design
- OTHER